Abstract
Hemoglobin, the protein responsible for the red color of blood plays a very important part in ‘life’- it transports oxygen, without which humans cannot survive. The idea of using purified Hemoglobin as a possible universal substitute for red blood cells has been around for almost a century. Hemoglobin formulations have important therapeutic applications, especially in case of trauma and war when requirements for blood may be very large. Manufacture of hemoglobin for use as a biopharmaceutical poses practical challenges, owing to dependence on human expired blood and fragility of the protein molecule. Biotechnology can play a critical role in breaking these barriers, by not only ensuring recombinant production of hemoglobin, but also enhancing stability of the molecule. The present article, based on a review of patents and available literature gives an insight into the IPR and technological issues involved in the commercial production of this ‘life-saving’ protein. There are more than 250 patents worldwide related to hemoglobin formulation, crosslinking and determination.
Keywords: Hemoglobin, haemoglobin, biopharmaceutical recombinant formulation, cross-linking, polymerization, blood substitute, recombinant hemoglobin, patents
Recent Patents on Biotechnology
Title: IPR and Technological Issues Regarding a Biopharmaceutical Formulation -Hemoglobin
Volume: 2 Issue: 1
Author(s): Parikshit Bansal, Chandrashekhar Honrao and Uttam C. Banerjee
Affiliation:
Keywords: Hemoglobin, haemoglobin, biopharmaceutical recombinant formulation, cross-linking, polymerization, blood substitute, recombinant hemoglobin, patents
Abstract: Hemoglobin, the protein responsible for the red color of blood plays a very important part in ‘life’- it transports oxygen, without which humans cannot survive. The idea of using purified Hemoglobin as a possible universal substitute for red blood cells has been around for almost a century. Hemoglobin formulations have important therapeutic applications, especially in case of trauma and war when requirements for blood may be very large. Manufacture of hemoglobin for use as a biopharmaceutical poses practical challenges, owing to dependence on human expired blood and fragility of the protein molecule. Biotechnology can play a critical role in breaking these barriers, by not only ensuring recombinant production of hemoglobin, but also enhancing stability of the molecule. The present article, based on a review of patents and available literature gives an insight into the IPR and technological issues involved in the commercial production of this ‘life-saving’ protein. There are more than 250 patents worldwide related to hemoglobin formulation, crosslinking and determination.
Export Options
About this article
Cite this article as:
Bansal Parikshit, Honrao Chandrashekhar and Banerjee C. Uttam, IPR and Technological Issues Regarding a Biopharmaceutical Formulation -Hemoglobin, Recent Patents on Biotechnology 2008; 2 (1) . https://dx.doi.org/10.2174/187220808783330901
DOI https://dx.doi.org/10.2174/187220808783330901 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronic Granulomatous Disease in Childhood
Current Pediatric Reviews Inhibition of Mitochondrial Membrane Permeability as a Putative Pharmacological Target for Cardioprotection
Current Medicinal Chemistry The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery
Current Vascular Pharmacology Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Targeting the p53 Pathway of Apoptosis
Current Pharmaceutical Design Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) Statins and Ischaemia Reperfusion Injury: A Molecular Biological Review
Current Vascular Pharmacology Emerging Therapy Options in Heparin-Induced Thrombocytopenia
Cardiovascular & Hematological Agents in Medicinal Chemistry Natural Anti-inflammatory Compounds as Drug Candidates in Alzheimer’s Disease
Current Medicinal Chemistry From the Oxygen to the Organ Protection: Erythropoietin as Protagonist in Internal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Regulation of Xanthine Oxidase Activity by Substrates at Active Sites via Cooperative Interactions between Catalytic Subunits: Implication to Drug Pharmacokinetics
Current Medicinal Chemistry Cardiac Remodeling and Exercise Training in Hypertension
Current Hypertension Reviews subject Index To Volume 2
Current Medicinal Chemistry - Central Nervous System Agents The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Current Drug Targets Inflammatory Mechanisms in Atherosclerosis: The Impact of Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Molecular Targets of Diabetic Vascular Complications and Potential New Drugs
Current Drug Targets Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression
Current Drug Targets Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke
Current Pharmaceutical Design